Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Showing 1 to 47 of 47

TitleReference numberPublishedLast updated
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Early and locally advanced breast cancer: diagnosis and managementNG101
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerMTG72
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Advanced breast cancer: diagnosis and treatmentCG81
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancerDG8
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2TA257
Breast reconstruction using lipomodelling after breast cancer treatmentIPG417
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Endoscopic mastectomy and endoscopic wide local excision for breast cancerIPG296
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excisionIPG268
Gemcitabine for the treatment of metastatic breast cancerTA116
Endoscopic axillary lymph node retrieval for breast cancerIPG147
Interstitial laser therapy for breast cancerIPG89
Improving outcomes in breast cancerCSG1
Guidance on the use of trastuzumab for the treatment of advanced breast cancerTA34

Results per page

  1. 10
  2. 25
  3. 50
  4. All